What's priced into CorVel Corporation?
What do you have to believe to make money in CorVel Corporation at $69.27? The stock trades at 30.8x trailing earnings and its own trailing growth runs about 19% a year. The question is where do we go from here?
Growth down the side, exit multiple across the top, your five-year annualized return in each cell.
5-year annualized return · growth vs exit multiple
| EPS growth ↓ · Exit multiple → | 15.4x −50% | 23.1x −25% | 30.8x today | 38.5x +25% | 49.6x 5y median |
|---|---|---|---|---|---|
| −10% (decline) | −21% | −15% | −10% | −6% | −1% |
| 0% (no growth) | −13% | −6% | +0% | +5% | +10% |
| 10% (half) | −5% | +4% | +10% | +15% | +21% |
| 19% (trailing 3y) | +4% | +13% | +19% | +25% | +31% |
| 24% (beat) | +8% | +17% | +24% | +30% | +37% |
| 29% (big beat) | +12% | +22% | +29% | +35% | +42% |
“The bet you're really making is that companies keep hiring CorVel to handle medical bills when a worker gets hurt, and that CorVel keeps using software to lower those bills before anyone pays them. The right tail is the same bill-review engine gaining business from ordinary health plans.”
From our CRVL write-up.
Read the CRVL write-up →Method. Trailing diluted EPS of $2.25 (price $69.27 ÷ 30.8x trailing P/E; data from Financial Modeling Prep, September 12, 2026). Exit multiples are anchored to the stock itself: 50% and 25% below today's multiple, today's, 25% above, and its own five-fiscal-year median of 49.6x. Growth rows are anchored to the company’s own trailing growth: a decline at half the center rate, zero, half, the center, 25% above, and 50% above. Cell shading scales with the return, green positive, red negative. Each cell: EPS compounds at the row's rate for five years, the stock is valued at the column's multiple in year five, and the result is the annualized return against today's price. Dividends and buybacks excluded. An illustrative surface, not a forecast and not a call.